The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients

被引：13
|
作者：
Amin, Arwa M. [1 ]
Chin, Lim Sheau [1 ]
Noor, Dzul Azri Mohamed [1 ]
Mostafa, Hamza [1 ]
Kader, Muhamad Ali S. K. Abdul [1 ,2 ]
Hay, Yuen Kah [1 ]
Ibrahim, Baharudin [1 ]
机构：
[1] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia
[2] Hosp Pulau Pinang, Cardiol Dept, George Town, Penang, Malaysia
来源：
THROMBOSIS RESEARCH | 2017年 / 158卷
关键词：
CYP2C19; Clopidogrel; Dual antiplatelet therapy (DAPT); Coronary artery disease patients; VerifyNow; High on treatment platelets reactivity; CLINICAL-OUTCOMES; THERAPY; IMPACT; RISK;
D O I：
10.1016/j.thromres.2017.07.032
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：22 / 24
页数：3
相关论文
共 50 条
  • [1] CYP2C19 GENETIC POLYMORPHISM ON CLOPIDOGREL RESPONSE IN VIETNAMESE PATIENTS WITH CORONARY STENTING
    Kim, N. T.
    Nguyen, M. N. T.
    Do, D. L.
    Nguyen, Q. H.
    Nguyen, T. T. T.
    Truong, T. H.
    ATHEROSCLEROSIS, 2020, 315 : E83 - E84
  • [2] The impact of CYP2C19 genetic mutation and non-genetic factors on the incidence of major adverse cardiovascular events in patients treated with clopidogrel in Qatar
    Ali, Zainab
    Bader, Loulia
    Al-Masri, Dania
    Ali, Mariam
    Arafa, Salah
    Arabi, Abdulrahman
    Mohammed, Shaban
    Rizk, Nasser
    Mraiche, Fatima
    Elewa, Hazem
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 47 (04) : 609 - 609
  • [3] Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease
    Liu Xiao-li
    Wang Zhi-jian
    Yang Qing
    Ge Hai-long
    Gao Fei
    Liu Yu-yang
    Shi Dong-mei
    Zhao Ying-xin
    Zhou Yu-jie
    CHINESE MEDICAL JOURNAL, 2010, 123 (22) : 3178 - 3183
  • [4] Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease
    中华医学杂志(英文版), 2010, (22) : 3178 - 3183
  • [5] Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease
    LIU XiaoliWANG ZhijianYANG QingGE HailongGAO FeiLIU YuyangSHI Dongmei ZHAO Yingxin and ZHOU Yujie Department of CardiologyBeijing Anzhen HospitalCapital Medical UniversityBeijing China
    CHINESEMEDICALJOURNAL, 2010, (22)
  • [6] Study on the effect of CYP2C19 genetic polymorphism and plasma concentration on clopidogrel resistance
    Wu, Hui
    Chen, Xinli
    Ding, Yongli
    Deng, Yanglin
    Ma, Ruilan
    Chen, Xinyuan
    Li, Xuesong
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 34 (05) : 1685 - 1691
  • [7] Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease
    Erlinge, David
    James, Stefan
    Duvvuru, Suman
    Jakubowski, Joseph A.
    Wagner, Henrik
    Varenhorst, Christoph
    Tantry, Udaya S.
    Brown, Patricia B.
    Small, David
    Moser, Brian A.
    Sundseth, Scott S.
    Walker, Joseph R.
    Winters, Kenneth J.
    Gurbel, Paul A.
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (05) : 943 - 950
  • [8] Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite
    Boulenc, Xavier
    Djebli, Nassim
    Shi, Juan
    Perrin, Laurent
    Brian, William
    Van Horn, Robert
    Hurbin, Fabrice
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (01) : 187 - 197
  • [9] CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Antiplatelet Action of Clopidogrel
    El-Halabi, Mustapha M.
    Zgheib, Nathalie
    Mansour, Nabil M.
    Malli, Ahmad
    Ghaith, Ola A.
    Mahfouz, Rami
    Alam, Samir
    Sharara, Ala I.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2013, 62 (01) : 41 - 49
  • [10] ANTIPLATELET THERAPY WITH CLOPIDOGREL TAKING INTO ACCOUNT CYP2C19 GENETIC POLYMORPHISMS IN PATIENTS WITH CORONARY HEART DISEASE AFTER CORONARY ARTERY STENTING
    Uzokov, J.
    Alyavi, B.
    Abdullaev, A.
    Muxitdinova, O.
    Ubaydullaeva, Z.
    ATHEROSCLEROSIS, 2021, 331 : E265 - E265
12345